A lentiviral vector-based therapeutic vaccine encoding Ag85B-Rv3425 potently increases resistance to acute tuberculosis infection in mice

• Published in: Acta biochimica et biophysica Sinica Vol. 47; no. 8; pp. 588 - 596
• Main Authors: Yang, Enzhuo, Wang, Feifei, Xu, Ying, Wang, Honghai, Hu, Yong, Shen, Hongbo, Chen, Zheng W
• Format: Journal Article
• Language: English
• Published: China 01.08.2015
• Subjects: Acute Disease; Acyltransferases - immunology; Adaptive Immunity; Animals; Antigens, Bacterial - immunology; Bacterial Proteins - immunology; Genetic Vectors; Immunotherapy, Active; Lentivirus; Mice; Mycobacterium tuberculosis; Tuberculosis - immunology; Tuberculosis - prevention & control; Tuberculosis Vaccines - administration & dosage; Tuberculosis Vaccines - immunology; 小鼠; 急性感染; 慢病毒载体; 抗原特异性; 治疗性; 病毒疫苗; 结核分枝杆菌; 结核病; therapeutic vaccine; lentiviral vector; tuberculosis
• ISSN: 1672-9145; 1745-7270
• DOI: 10.1093/abbs/gmv059

Few treatment options for multidrug-resistant tuberculosis （TB） and extensively drug-resistant TB call attention to the development of novel therapeutic approaches for TB. Therapeutic vaccines are promising candidates because they can induce antigen-specific cellular immune responses, which play an important role in the elimination of Mycobacterium tuberculosis （MTB）. In this study, a novel lentiviral vector therapeutic vaccine for delivering MTB-specific fusion protein Ag85B-Rv3425 was constructed. Results showed that one single-injection of this recombinant lenti- virus vaccine could trigger antigen-specific Thl-type immune responses in mice. More importantly, mice with acute infection benefited a lot from a single-dose administration of this vaccine by mark- edly reduced MTB burdens in lungs and spleens as well as attenuated lesions in lungs compared with untreated mice. These results displayed good prospects of this novel vaccine for the immuno- therapy of TB.